Literature DB >> 18209762

Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Russell G Thornton1.   

Abstract

Entities:  

Year:  2008        PMID: 18209762      PMCID: PMC2190559          DOI: 10.1080/08998280.2008.11928368

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


× No keyword cloud information.
  29 in total

1.  Secret US report surfaces on antidepressants in children.

Authors:  Jeanne Lenzer
Journal:  BMJ       Date:  2004-08-07

2.  Learning the value of drugs--is rofecoxib a regulatory success story?

Authors:  Rebecca S Eisenberg
Journal:  N Engl J Med       Date:  2005-03-31       Impact factor: 91.245

3.  How the US drug safety system should be changed.

Authors:  Brian L Strom
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

4.  Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings.

Authors:  Peter Lurie; Cristina M Almeida; Nicholas Stine; Alexander R Stine; Sidney M Wolfe
Journal:  JAMA       Date:  2006-04-26       Impact factor: 56.272

5.  Dangerous deception--hiding the evidence of adverse drug effects.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2006-11-23       Impact factor: 91.245

6.  A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach.

Authors:  Peter D Jacobson; Wendy E Parmet
Journal:  JAMA       Date:  2007-01-10       Impact factor: 56.272

7.  Report criticizes lack of FDA oversight.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

8.  Protecting the health of the public--Institute of Medicine recommendations on drug safety.

Authors:  Bruce M Psaty; Sheila P Burke
Journal:  N Engl J Med       Date:  2006-10-09       Impact factor: 91.245

9.  Drug safety reform at the FDA--pendulum swing or systematic improvement?

Authors:  Mark McClellan
Journal:  N Engl J Med       Date:  2007-04-13       Impact factor: 91.245

10.  The FDA and the case of Ketek.

Authors:  David B Ross
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.